Project Details
Description
DDI2 plays an important role in the development of resistance in multiple myeloma (MM) to current state-of-the-art treatment with protease inhibitors. Together with the Karl Landsteiner University of Health Sciences and the University Hospital St. Pölten, the effects of DDI2 modulation were investigated to determine whether an added value can be achieved in the treatment of multiple myeloma.
| Short title | DDI2 in multiplem Myelom |
|---|---|
| Status | Finished |
| Effective start/end date | 28/02/23 → 12/01/26 |
Collaborative partners
- IMC Krems University of Applied Sciences
- Karl Landsteiner Privatuniversität für Gesundheitswissenschaften GmbH (Project partner) (lead)
Funding
- Gesellschaft für Forschungsförderung Niederösterreich
UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
IMC Research Focuses
- Medical biotechnology
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.